Immunotherapy Keytruda Exceeds Opdivo in Q2 sales

 Immunotherapy Keytruda Exceeds Opdivo in Q2 sales

Immunotherapy Keytruda Exceeds Opdivo in Q2 sales

Shots:
  •  Keytruda sold $1.67Bn, 90% Y-o-Y, narrowly beating Opdivo’s $1.63Bn in Q2’18
  •  Higher sales are observed as Keytruda in combination with Lilly’s Alimta and platinum chemo improves OS with 51% reduction in death in NSCLC patient vs chemo
  • Above combination is showing immense attraction from Physicians despite of pending FDA approval
Click here to read full press release/ article | Ref: Merck | Image: Forbes

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post